Hints on perhaps the next shoe to drop: no further info from any preclinical study happening referenced from the March shareholder letter:

“Two previously announced preclinical studies in TNBC that will identify treatment strategies to optimize the design of future studies are now underway. A third study has begun to further examine the apparent mechanism behind the observed increase in survival as compared to existing treatment paths. In the meantime, we will continue discussions with KOLs about the possibility of initiating a follow-up study in patients with mTNBC on an abbreviated timeline, based on currently available data.”

Clearly the mTNBC pot is being stirred, curious if they are sitting on anything else coming out of the preclinical studies which would add color or further enhance partnership interest.